GC Labcell Releases Research Data on Combination Therapy with NK Cell Therapy
[Asia Economy, Reporter Jo Hyunui] GC Labcell announced on June 11 that it has released research data on the combination therapy of NK (Natural Killer) cell therapy, which is regarded as a next-generation immuno-oncology treatment.
GC Labcell will present interim results from a Phase 1/2 clinical trial combining its NK cell therapy 'MG4101' with the anti-cancer antibody therapy 'Rituximab' in a poster session at the 25th European Hematology Association (EHA) Annual Congress, which is being held online from June 11 to 21.
Natural Killer (NK) cells, which have the characteristic of autonomously attacking cancer cells or viruses in the body, are known to maximize therapeutic effects when combined with antibody therapies. Although numerous studies are being conducted worldwide, there are very few cases where the efficacy of cultured NK cells combined with antibodies has been proven.
MG4101 eliminates cancer cells by utilizing innate immune cells, specifically natural killer cells, within the body. It is produced using proprietary culturing technology, resulting in high purity, and can be mass-produced for use in other individuals without side effects.
In studies conducted on lymphoma patients, the combination therapy of MG4101 and Rituximab has demonstrated excellent interim results in terms of both efficacy and safety.
As a result of the combination therapy, partial remission (PR) was observed in 50% of all patients, and no dose-limiting toxicity (DLT) or other adverse effects were reported. The company noted that since this clinical study targeted patients who had failed conventional treatments, the combination therapy could become an important treatment option for lymphoma patients.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
Hwang Youkyung, Director of the Cell Therapy Research Institute at GC Labcell, stated, "We are steadily increasing the development potential of MG4101 in combination with antibody therapies," and added, "Based on our global-level capabilities in mass production and cryopreservation, we will accelerate the development of next-generation NK cell therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
